Brian Mi

President, Asia Pacific, IQVIA
​IQVIA

Dr. Brian Mi, is the President of Asia Pacific for IQVIA, leading IQVIA operations in Greater China,

Australia, New Zealand, South Korea, and Southeast Asia countries.

Brian is an industry veteran with over 30 years of experience in pharmaceutical research and product commercialization in USA and China. He joined IQVIA (IMS Health) in 2008, and since then has served in leadership positions with increasing responsibilities in Commercial and R&D operations across China and Asia Pacific region.

Prior to IQVIA, Brian held global management roles at Pfizer and Amylin Pharmaceuticals in new product marketing, R&D strategy, and corporate planning.

Brian received a Ph.D. degree in pharmaceutical chemistry from the Ohio State University and an M.B.A. from the University of Chicago Booth School of Business. 

Speech title & Synopsis

Global trends and future opportunities in pharma

This session will focus on the pharmaceutical market from both global and Asian angles. The next five years will see accelerated growth in the global pharmaceutical market, driven by developed markets like the US. Post-Covid, pharmaceutical companies shifted funding toward research and development (R&D), focusing on non-communicable diseases. In 2023, major pharma players witnessed a resurgence in mergers and acquisitions, and substantial R&D investments. Regulatory reforms have enhanced flexibility, harmonization, speed, and simplicity, facilitating the expedited launch of innovative medicines. Artificial intelligence (AI) plays a transformative role across drug discovery, clinical development, and commercialization. 

Asia, renowned as the world’s largest and most diverse continent, captures attention not only for the size of the market but also its potential for innovation.